The p38α mitogen-activated protein kinase as a central nervous system drug discovery target
| Autor: | Lúcia Maria Vieira de Almeida, Linda J. Van Eldik, D. Martin Watterson, Aaron S. Borders |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Central Nervous System
MAPK/ERK pathway Review Biology lcsh:RC321-571 Proinflammatory cytokine Mitogen-Activated Protein Kinase 14 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Animals Humans ASK1 Enzyme Inhibitors Phosphorylation Protein kinase A lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry 030304 developmental biology 0303 health sciences Molecular Structure Drug discovery Kinase General Neuroscience lcsh:QP351-495 Neurodegenerative Diseases 3. Good health Cell biology lcsh:Neurophysiology and neuropsychology Drug Design Mitogen-activated protein kinase biology.protein Signal transduction 030217 neurology & neurosurgery Signal Transduction |
| Zdroj: | BMC Neuroscience BMC Neuroscience, Vol 9, Iss Suppl 2, p S12 (2008) |
| ISSN: | 1471-2202 |
| DOI: | 10.1186/1471-2202-9-s2-s12 |
| Popis: | Protein kinases are critical modulators of a variety of cellular signal transduction pathways, and abnormal phosphorylation events can be a cause or contributor to disease progression in a variety of disorders. This has led to the emergence of protein kinases as an important new class of drug targets for small molecule therapeutics. A serine/threonine protein kinase, p38α mitogen-activated protein kinase (MAPK), is an established therapeutic target for peripheral inflammatory disorders because of its critical role in regulation of proinflammatory cytokine production. There is increasing evidence that p38α MAPK is also an important regulator of proinflammatory cytokine levels in the central nervous system, raising the possibility that the kinase may be a drug discovery target for central nervous system disorders where cytokine overproduction contributes to disease progression. Development of bioavailable, central nervous system-penetrant p38α MAPK inhibitors provides the required foundation for drug discovery campaigns targeting p38α MAPK in neurodegenerative disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|